26 January 2021 FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, notes the following announcement released today concerning investee company EMMAC Life Sciences ( EMMAC ). FastForward has a 2.3% interest in the issued stock of EMMAC. EMMAC Life Sciences Group and Boiron selected for French Medical Cannabis trial Only European Company selected by the French Agency for the Safety of Medicines and Health Products (ANSM) 26 January 2021, London. EMMAC Life Sciences Group ( EMMAC or the Group or the Company ), Europe s largest independent cannabis company, is pleased to announce that in partnership with Paris Euronext listed Boiron (BOI.PA), it has been selected by the French Agency for the Safety of Medicines and Health Products ( ANSM ) as one of the suppliers for the forthcoming
CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management s estimates or opinions change.
France chooses companies to supply free medical cannabis for trial program Published January 25, 2021 | By Alfredo Pascual
The French Agency for the Safety of Medicines and Health Products (ANSM) selected the companies that will supply France’s medical cannabis pilot program that’s intended to provide free products to patients enrolled in the trial.
Cannabis companies from Australia, Canada, Israel and the United Kingdom – in partnership with French pharmaceutical distributors – will provide the products for up to 3,000 patients and will not receive any money for supplying the medical cannabis.
French authorities selected main suppliers, as well as substitute suppliers to cover any shortfalls.